Bruno Silva-Santos
Company: University of Lisbon
Job title: Associate Professor
Bio:
Bruno Silva-Santos is a Group Leader and Vice-Director of Instituto de Medicina Molecular (iMM), and Associate Professor at the Faculty of Medicine of the University of Lisbon (Portugal). He did his PhD in Immunology with Michael J. Owen at Cancer Research UK (The London Research Institute, 1998-2002), and trained as a post-doc with Adrian Hayday at King’s College London (2002-2005). Since establishing his independent group in 2006 at iMM in Lisbon, Bruno Silva-Santos has received Starting and Consolidator Grants from the European Research Council (ERC) and Installation and Young Investigator Grants from the European Molecular Biology Organization (EMBO). His research is mostly dedicated to gamma-delta T cells, having dissected novel molecular mechanisms of their differentiation and tumour cell recognition, published in over 90 papers in top international peer-reviewed journals. In 2019, Bruno Silva-Santos was elected EMBO Member in recognition of his scientific contributions. His translational work on Immuno-Oncology was further recognized with various awards and the nomination as Honorary Member of the European Academy of Tumour Immunology. His work also constituted the basis for a start-up company (founded in 2013) focused on cancer immunotherapy, Lymphact, in which he presided the Scientific Council; and was acquired in 2018 by GammaDelta Therapeutics (London, UK), where he now serves in the Scientific Advisory Board.
Seminars:
Live Q&A Discussion 3:10 pm
day: Day One
Vδ1 T Cell Expansion, Differentiation & Tumour Targeting 1:30 pm
• Molecular cues for Vδ1 T cell expansion and differentiation • Characterisation of “Delta One T (DOT) cells” as an expanded Vδ1 T cell product • Recognition and targeting of haematological tumours by DOT cells • Recognition and targeting of solid tumours by DOT cellsRead more
day: Day One
Vδ1 T Cell Expansion, Differentiation & Tumour Targeting 2:00 pm
• Molecular cues for Vδ1 T cell expansion and differentiation • Characterisation of “Delta One T (DOT) cells” as an expanded Vδ1 T cell product • Recognition and targeting of haematological tumours by DOT cells • Recognition and targeting of solid tumours by DOT cellsRead more
day: Day Two